Knick-knack PADIMAC
- 15 November 2018
- journal article
- editorial
- Published by American Society of Hematology in Blood
- Vol. 132 (20) , 2110-2111
Abstract
In this issue of Blood, Chapman et al1 have derived a 7-gene expression signature that predicts whether a newly diagnosed myeloma patient will respond to treatment with bortezomib when autologous stem cell transplant (ASCT) is not considered as part of the upfront therapy.Keywords
This publication has 7 references indexed in Scilit:
- Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple MyelomaBlood, 2018
- RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signatureBlood, 2018
- The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myelomaOncotarget, 2017
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsBlood, 2010
- Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myelomaBlood, 2006
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- Global Gene Expression Profiling in the Study of Multiple MyelomaInternational Journal of Hematology, 2003